Oncogenic Protein Kinase D3 Regulating Networks in Invasive Breast Cancer

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2017 Jun 29

PMID 28656000

Citations 9

Authors

Yan Liu

Jian Li

Jun Zhang

Zhenghong Yu

Shiyi Yu

Lele Wu

Yuzhi Wang

Xue Gong

Chenxi Wu

Xiuxiu Cai

Lin Mo

Mingya Wang

Jun Gu

Liming Chen

Affiliations

Soon will be listed here.

Abstract

Protein Kinase D3 (PRKD3) functions as an important oncogenic driver in invasive breast cancer, which is the leading cause of women mortality. However, PRKD3 regulating network is largely unknown. In this study, we systematically explored PRKD3 regulating networks via investigating phosphoproteome, interactome and transcriptome to uncover the molecular mechanism of PRKD3 in invasive breast cancer. Using iTRAQ, 270 proteins were identified as PRKD3 regulated phosphoproteins from 4619 phosphosites matching 3666 phosphopeptides from 2016 phosphoproteins with p-value <0.005. Transcriptome analysis using affymetrix microarray identified 45 PRKD3 regulated genes, in which 20 genes were upregulated and 25 genes were downregulated with p-value <0.005 upon silencing . Using Co-IP in combination of MS identification, 606 proteins were identified to be PRKD3 interacting proteins from 2659 peptides. Further network analysis of PRKD3 regulated phosphoproteins, interacting proteins and regulated genes, reveals 19 hub nodes, including ELAVL1, UBC and BRCA1. UBC was recognized as the most common hub node in PRKD3 regulating networks. The enriched pathway analysis reveals that PRKD3 regulates pathways contributing to multiple cancer related events, including cell cycle, migration and others. Enrichment of cell cycle and cell mobility related pathways across PRKD3 networks, explained the observations that depletion of oncogenic PRKD3 led to alternation of cell cycle and decrease of cell migration ability. Taken together, our current study provided valuable information on the roles as well as the molecular mechanisms of PRKD3 in invasive breast cancer.

Citing Articles

Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes.

Park J, Pena-Tauber A, Talozzi L, Greicius M, Guen Y Nat Commun. 2025; 16(1):2064.

PMID: 40021682 PMC: 11871019. DOI: 10.1038/s41467-025-57315-6.

Transcriptome Analysis Suggests PKD3 Regulates Proliferative Glucose Metabolism, Calcium Homeostasis and Microtubule Dynamics After MEF Spontaneous Immortalization.

Loaiza-Moss J, Braun U, Leitges M Int J Mol Sci. 2025; 26(2).

PMID: 39859313 PMC: 11765705. DOI: 10.3390/ijms26020596.

Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance.

Li J, Fang K, Choppavarapu L, Yang K, Yang Y, Wang J Clin Epigenetics. 2021; 13(1):175.

PMID: 34535185 PMC: 8447690. DOI: 10.1186/s13148-021-01167-6.

Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis.

Hulverson M, Choi R, Vidadala R, Whitman G, Vidadala V, Ojo K ACS Infect Dis. 2021; 7(5):1200-1207.

PMID: 33565854 PMC: 8559537. DOI: 10.1021/acsinfecdis.0c00803.

The oncogenic role of protein kinase D3 in cancer.

Liu Y, Song H, Zhou Y, Ma X, Xu J, Yu Z J Cancer. 2021; 12(3):735-739.

PMID: 33403031 PMC: 7778554. DOI: 10.7150/jca.50899.

References

Doppler H, Bastea L, Borges S, Spratley S, Pearce S, Storz P . Protein kinase d isoforms differentially modulate cofilin-driven directed cell migration. PLoS One. 2014; 9(5):e98090. PMC: 4026536. DOI: 10.1371/journal.pone.0098090. View

Hao Q, McKenzie R, Gan H, Tang H . Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells. Anticancer Res. 2013; 33(2):393-9. View

LaValle C, George K, Sharlow E, Lazo J, Wipf P, Wang Q . Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010; 1806(2):183-92. PMC: 2947595. DOI: 10.1016/j.bbcan.2010.05.003. View

Shigemizu D, Hu Z, Hung J, Huang C, Wang Y, DeLisi C . Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012; 8(2):e1002347. PMC: 3276504. DOI: 10.1371/journal.pcbi.1002347. View

Borges S, Perez E, Thompson E, Radisky D, Geiger X, Storz P . Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. Mol Cancer Ther. 2015; 14(6):1306-16. PMC: 4458391. DOI: 10.1158/1535-7163.MCT-14-0945. View

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

Sarcevic B, Mawson A, Baker R, Sutherland R . Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation. EMBO J. 2002; 21(8):2009-18. PMC: 125963. DOI: 10.1093/emboj/21.8.2009. View

Wang Q . PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci. 2006; 27(6):317-23. DOI: 10.1016/j.tips.2006.04.003. View

Gautier L, Cope L, Bolstad B, Irizarry R . affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15. DOI: 10.1093/bioinformatics/btg405. View

10.

Huck B, Duss S, Hausser A, Olayioye M . Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem. 2013; 289(6):3138-47. PMC: 3916519. DOI: 10.1074/jbc.M113.502633. View

11.

DeSantis C, Fedewa S, Sauer A, Kramer J, Smith R, Jemal A . Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2015; 66(1):31-42. DOI: 10.3322/caac.21320. View

12.

Rykx A, De Kimpe L, Mikhalap S, Vantus T, Seufferlein T, Vandenheede J . Protein kinase D: a family affair. FEBS Lett. 2003; 546(1):81-6. DOI: 10.1016/s0014-5793(03)00487-3. View

13.

Fu Y, Rubin C . Protein kinase D: coupling extracellular stimuli to the regulation of cell physiology. EMBO Rep. 2011; 12(8):785-96. PMC: 3147268. DOI: 10.1038/embor.2011.139. View

14.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

15.

Lu R, Wu S, Zhang Y, Xia Y, Zhou Z, Kato I . Salmonella Protein AvrA Activates the STAT3 Signaling Pathway in Colon Cancer. Neoplasia. 2016; 18(5):307-316. PMC: 4887618. DOI: 10.1016/j.neo.2016.04.001. View

16.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

17.

Chen J, Deng F, Singh S, Wang Q . Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 2008; 68(10):3844-53. DOI: 10.1158/0008-5472.CAN-07-5156. View

18.

Xia J, Gill E, Hancock R . NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat Protoc. 2015; 10(6):823-44. DOI: 10.1038/nprot.2015.052. View

19.

Huck B, Kemkemer R, Franz-Wachtel M, Macek B, Hausser A, Olayioye M . GIT1 phosphorylation on serine 46 by PKD3 regulates paxillin trafficking and cellular protrusive activity. J Biol Chem. 2012; 287(41):34604-13. PMC: 3464566. DOI: 10.1074/jbc.M112.374652. View

20.

Rozengurt E, Rey O, Waldron R . Protein kinase D signaling. J Biol Chem. 2005; 280(14):13205-8. DOI: 10.1074/jbc.R500002200. View